GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research

(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes.
In a phase III trial…